Guardant Shield Blood Test Gains Coverage from UnitedHealth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: stocktwits
- Coverage Expansion: UnitedHealth, the leading U.S. health insurer, announced that effective August 1, Guardant's Shield product will be covered for colorectal cancer screening, significantly enhancing Guardant's market opportunities and sales potential.
- Stock Surge: Following UnitedHealth's announcement, shares of Guardant Health (GH) surged nearly 10% on Wednesday, and if this gain holds, it is expected to reach five-year highs, reflecting optimistic market sentiment towards the company's prospects.
- Analyst Optimism: BTIG raised GH's price target from $150 to $190, implying nearly 27% upside from Tuesday's closing price, and noted that the timing of this coverage is 1-2 years ahead of expectations, potentially prompting other commercial payors to follow suit.
- Retail Investor Sentiment: According to Stocktwits, retail sentiment towards GH remained bullish over the past 24 hours, with the stock gaining approximately 61% year-to-date and more than tripling in value over the past 12 months, significantly outperforming the S&P index.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GH
Wall Street analysts forecast GH stock price to fall
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 168.820
Low
105.00
Averages
124.69
High
155.00
Current: 168.820
Low
105.00
Averages
124.69
High
155.00
About GH
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UnitedHealth Expands Coverage for Shield Blood Test for Colorectal Cancer
- Expanded Coverage: UnitedHealth Group (UHG), the largest commercial insurer in the U.S., updates its policy to provide access to the FDA-approved Shield blood test for colorectal cancer screening to over 100 million individuals, marking a significant advancement in cancer screening accessibility.
- Innovative Testing Method: The Shield test is the first FDA-approved blood test included in both the American Cancer Society (ACS) and National Comprehensive Cancer Network (NCCN) guidelines, offering a non-invasive screening option that can be completed with a simple blood draw during routine doctor visits, significantly enhancing screening accessibility.
- Addressing Rising Cancer Rates: With increasing colorectal cancer rates among younger individuals, UHG's policy update provides the latest screening innovation for average-risk individuals aged 45 and older, aiming to reduce cancer mortality rates in younger populations and improve early detection rates.
- Strong Clinical Performance: The Shield test's robust clinical performance, supported by real-world evidence published in the New England Journal of Medicine, further solidifies its position as a preferred method for colorectal cancer screening, aiding Guardant Health's commercial expansion in the precision oncology sector.
See More
Guardant Shield Blood Test Gains Coverage from UnitedHealth
- Coverage Expansion: UnitedHealth, the leading U.S. health insurer, announced that effective August 1, Guardant's Shield product will be covered for colorectal cancer screening, significantly enhancing Guardant's market opportunities and sales potential.
- Stock Surge: Following UnitedHealth's announcement, shares of Guardant Health (GH) surged nearly 10% on Wednesday, and if this gain holds, it is expected to reach five-year highs, reflecting optimistic market sentiment towards the company's prospects.
- Analyst Optimism: BTIG raised GH's price target from $150 to $190, implying nearly 27% upside from Tuesday's closing price, and noted that the timing of this coverage is 1-2 years ahead of expectations, potentially prompting other commercial payors to follow suit.
- Retail Investor Sentiment: According to Stocktwits, retail sentiment towards GH remained bullish over the past 24 hours, with the stock gaining approximately 61% year-to-date and more than tripling in value over the past 12 months, significantly outperforming the S&P index.
See More
UnitedHealth to Cover Guardant Shield Test, Boosting GH Stock
- Positive Market Reaction: Guardant Health's stock surged approximately 7% in Wednesday morning trading following UnitedHealth Group's announcement to cover the blood-based cancer screening test, Guardant Shield, starting August 1, indicating strong market enthusiasm for the news.
- Expanded Coverage: The Guardant Shield test, which screens for colorectal cancer, will benefit more patients due to UnitedHealth's coverage; Citi analyst Patrick Donnelly noted that this expansion unlocks a new cohort of patients, potentially driving significant average selling price (ASP) benefits.
- Growth Potential Highlighted: Analysts are optimistic about Guardant Health's prospects, with RBC upgrading its rating to Outperform, suggesting that this coverage expansion will serve as a key catalyst for the company's growth, further boosting market confidence.
- Industry Dynamics Under Scrutiny: While the HHS expresses skepticism regarding international cancer risk assessments, Guardant Health's products are still viewed as critical for future growth, particularly against the backdrop of increasing innovation and demand in the cancer screening sector.
See More
Guardant Health Shares Surpass Analyst Target Price
- Stock Performance: Guardant Health Inc (Ticker: GH) recently traded at $149.22, surpassing the average analyst 12-month target price of $145.50, indicating optimistic market sentiment that may attract more investor interest.
- Analyst Reactions: When a stock hits its target price, analysts may either downgrade their valuation or raise their target; currently, 22 analysts have target prices ranging from $125.00 to $190.00, with a standard deviation of $19.759, reflecting varied expectations for the company's future performance.
- Investor Signal: The stock's rise above the target price provides a good signal for investors to reassess the company, prompting them to consider whether $145.50 is merely a temporary stop or a potential launch point for further gains, influencing their investment decisions.
- Wisdom of Crowds: The average target price reflects a
See More
Micron's Strong Earnings Boost Chip Stocks
- Strong Earnings: Micron reported quarterly revenue of $6 billion, exceeding market expectations and causing its stock to surge 10% in after-hours trading, reflecting robust performance in the memory market.
- Optimistic Guidance: The company provided a positive outlook for the upcoming quarter, projecting a 15% revenue growth, indicating strong confidence in market demand, which may attract more investor interest.
- Industry Ripple Effect: Micron's impressive results not only boosted its own stock but also lifted other memory and chip-related companies, creating a positive ripple effect across the industry and enhancing overall market confidence in the semiconductor sector.
- Inflation Data Watch: With the Fed set to release its favored inflation gauge, market expectations regarding future monetary policy will further influence tech stock performance, prompting investors to closely monitor related developments.
See More
Futures Rise as South Korea's Kospi Index Jumps
- Market Rebound: Following the Nasdaq's breach of support, South Korea's Kospi index surged, leading to a rise in futures, indicating a potential recovery in investor confidence that may attract more capital inflows.
- Stock Volatility: FedEx and AI chip company Cerebras experienced significant declines late in the trading session, reflecting market concerns about their future prospects, which could undermine investor confidence in their respective sectors.
- Micron Earnings Watch: With Micron's earnings report on the horizon, the market is keenly focused on its performance, as analysts expect its results to significantly impact the semiconductor industry, potentially prompting a reevaluation by investors.
- Technical Support Levels: The Nasdaq's support level being breached may lead to increased market volatility in the short term, necessitating investors to closely monitor subsequent trends to adjust their investment strategies accordingly.
See More
UnitedHealth Expands Coverage for Shield Blood Test for Colorectal Cancer
- Expanded Coverage: UnitedHealth Group (UHG), the largest commercial insurer in the U.S., updates its policy to provide access to the FDA-approved Shield blood test for colorectal cancer screening to over 100 million individuals, marking a significant advancement in cancer screening accessibility.
- Innovative Testing Method: The Shield test is the first FDA-approved blood test included in both the American Cancer Society (ACS) and National Comprehensive Cancer Network (NCCN) guidelines, offering a non-invasive screening option that can be completed with a simple blood draw during routine doctor visits, significantly enhancing screening accessibility.
- Addressing Rising Cancer Rates: With increasing colorectal cancer rates among younger individuals, UHG's policy update provides the latest screening innovation for average-risk individuals aged 45 and older, aiming to reduce cancer mortality rates in younger populations and improve early detection rates.
- Strong Clinical Performance: The Shield test's robust clinical performance, supported by real-world evidence published in the New England Journal of Medicine, further solidifies its position as a preferred method for colorectal cancer screening, aiding Guardant Health's commercial expansion in the precision oncology sector.
See More
Guardant Shield Blood Test Gains Coverage from UnitedHealth
- Coverage Expansion: UnitedHealth, the leading U.S. health insurer, announced that effective August 1, Guardant's Shield product will be covered for colorectal cancer screening, significantly enhancing Guardant's market opportunities and sales potential.
- Stock Surge: Following UnitedHealth's announcement, shares of Guardant Health (GH) surged nearly 10% on Wednesday, and if this gain holds, it is expected to reach five-year highs, reflecting optimistic market sentiment towards the company's prospects.
- Analyst Optimism: BTIG raised GH's price target from $150 to $190, implying nearly 27% upside from Tuesday's closing price, and noted that the timing of this coverage is 1-2 years ahead of expectations, potentially prompting other commercial payors to follow suit.
- Retail Investor Sentiment: According to Stocktwits, retail sentiment towards GH remained bullish over the past 24 hours, with the stock gaining approximately 61% year-to-date and more than tripling in value over the past 12 months, significantly outperforming the S&P index.
See More
UnitedHealth to Cover Guardant Shield Test, Boosting GH Stock
- Positive Market Reaction: Guardant Health's stock surged approximately 7% in Wednesday morning trading following UnitedHealth Group's announcement to cover the blood-based cancer screening test, Guardant Shield, starting August 1, indicating strong market enthusiasm for the news.
- Expanded Coverage: The Guardant Shield test, which screens for colorectal cancer, will benefit more patients due to UnitedHealth's coverage; Citi analyst Patrick Donnelly noted that this expansion unlocks a new cohort of patients, potentially driving significant average selling price (ASP) benefits.
- Growth Potential Highlighted: Analysts are optimistic about Guardant Health's prospects, with RBC upgrading its rating to Outperform, suggesting that this coverage expansion will serve as a key catalyst for the company's growth, further boosting market confidence.
- Industry Dynamics Under Scrutiny: While the HHS expresses skepticism regarding international cancer risk assessments, Guardant Health's products are still viewed as critical for future growth, particularly against the backdrop of increasing innovation and demand in the cancer screening sector.
See More
Guardant Health Shares Surpass Analyst Target Price
- Stock Performance: Guardant Health Inc (Ticker: GH) recently traded at $149.22, surpassing the average analyst 12-month target price of $145.50, indicating optimistic market sentiment that may attract more investor interest.
- Analyst Reactions: When a stock hits its target price, analysts may either downgrade their valuation or raise their target; currently, 22 analysts have target prices ranging from $125.00 to $190.00, with a standard deviation of $19.759, reflecting varied expectations for the company's future performance.
- Investor Signal: The stock's rise above the target price provides a good signal for investors to reassess the company, prompting them to consider whether $145.50 is merely a temporary stop or a potential launch point for further gains, influencing their investment decisions.
- Wisdom of Crowds: The average target price reflects a
See More
Micron's Strong Earnings Boost Chip Stocks
- Strong Earnings: Micron reported quarterly revenue of $6 billion, exceeding market expectations and causing its stock to surge 10% in after-hours trading, reflecting robust performance in the memory market.
- Optimistic Guidance: The company provided a positive outlook for the upcoming quarter, projecting a 15% revenue growth, indicating strong confidence in market demand, which may attract more investor interest.
- Industry Ripple Effect: Micron's impressive results not only boosted its own stock but also lifted other memory and chip-related companies, creating a positive ripple effect across the industry and enhancing overall market confidence in the semiconductor sector.
- Inflation Data Watch: With the Fed set to release its favored inflation gauge, market expectations regarding future monetary policy will further influence tech stock performance, prompting investors to closely monitor related developments.
See More
Futures Rise as South Korea's Kospi Index Jumps
- Market Rebound: Following the Nasdaq's breach of support, South Korea's Kospi index surged, leading to a rise in futures, indicating a potential recovery in investor confidence that may attract more capital inflows.
- Stock Volatility: FedEx and AI chip company Cerebras experienced significant declines late in the trading session, reflecting market concerns about their future prospects, which could undermine investor confidence in their respective sectors.
- Micron Earnings Watch: With Micron's earnings report on the horizon, the market is keenly focused on its performance, as analysts expect its results to significantly impact the semiconductor industry, potentially prompting a reevaluation by investors.
- Technical Support Levels: The Nasdaq's support level being breached may lead to increased market volatility in the short term, necessitating investors to closely monitor subsequent trends to adjust their investment strategies accordingly.
See More
